Argenx Plunges 12.99% on Missed Revenue, Barclays Cut

On May 8, 2025, Argenx's stock experienced a significant drop of 12.99% in pre-market trading, marking a notable decline in its share price.

Argenx reported its first-quarter 2025 financial results, highlighting the breadth and depth of its immunology pipeline. The company is advancing multiple first-in-class product candidates with potential across various therapeutic areas. This progress in its pipeline is a key driver for the company's future growth prospects.

In its Q1 earnings report, Argenx achieved a GAAP EPS of $2.58, surpassing analyst expectations by $0.13. However, the company missed revenue expectations, which may have contributed to the stock's decline. The earnings report also indicated a swing from a loss of $1.04 per share a year earlier to a profit of $2.58 per diluted share, reflecting a significant improvement in the company's financial performance.

Barclays PLC reduced its holdings in Argenx shares by 87.3% during the fourth quarter, which could have influenced investor sentiment and contributed to the stock's decline. This reduction in holdings by a major institutional investor may have raised concerns among other investors about the company's future prospects.